Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Palo Alto

Division of Roche
paloalto.roche.com

Latest From Roche Palo Alto

Critical Collaborators

The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.
BioPharmaceutical Regulation

Recent Dealmaking (12/2002)

Summarizing the month in European dealmaking.

File Enrichment: The Way Out of Pharma's Productivity Crisis?

To address the problem of attrition during lead compound discovery and early development, some large drug firms - Pfizer perhaps both the most vocal and committed -- are banking on file enrichment and selection. Better-informed compound library construction and more efficient lead selection could double the useful hit rate, they say, in effect doubling the number of successful new drug introductions downstream. There's room for combining empirical and rational approaches; for example, combining novel fragments to extend diversity with privileged fragments (or scaffolds) that reflect rational assumptions about drug motifs. For now, however, the proposition of file enrichment is much more theory than reality, until it is shown to actually reduce attrition both before and during clinical development, and so improve productivity.
BioPharmaceutical Platform Technologies

Grunenthal Learns to Leverage

Grunenthal is reorganizing to become a better marketer, collaborator and innovator--a private firm that will thrive in the turbulent European market.
BioPharmaceutical North America
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Roche Bioscience
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Richard Powers, CFO
    James Woody, Pres. & Gen. Mgr.
    Stewart Kortez, Corp. VP, Tech. Affairs & Bus. Dev.
    Jack Bleau, VP, Sales & Mktg.
  • Contact Info
  • Roche Palo Alto
    Phone: (415) 855-5050
    3431 Hillview Ave.
    Palo Alto, CA 94304
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register